These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38965868)

  • 1. Curcumin and nano-curcumin applications in psychiatric disorders.
    Mohammadzadeh R; Fathi M; Pourseif MM; Omidi Y; Farhang S; Barzegar Jalali M; Valizadeh H; Nakhlband A; Adibkia K
    Phytother Res; 2024 Aug; 38(8):4240-4260. PubMed ID: 38965868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.
    Wang Z; Kemp DE; Chan PK; Fang Y; Ganocy SJ; Calabrese JR; Gao K
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):131-42. PubMed ID: 20875219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Role of Curcumin for the Treatment of Major Depressive Disorder.
    Lopresti AL
    CNS Drugs; 2022 Feb; 36(2):123-141. PubMed ID: 35129813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study.
    Kanchanatawan B; Tangwongchai S; Sughondhabhirom A; Suppapitiporn S; Hemrunrojn S; Carvalho AF; Maes M
    Neurotox Res; 2018 Apr; 33(3):621-633. PubMed ID: 29327213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin as a putative antidepressant.
    Seo HJ; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Pae CU
    Expert Rev Neurother; 2015 Mar; 15(3):269-80. PubMed ID: 25644944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The serotonin transporter in psychiatric disorders: insights from PET imaging.
    Spies M; Knudsen GM; Lanzenberger R; Kasper S
    Lancet Psychiatry; 2015 Aug; 2(8):743-755. PubMed ID: 26249305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumin for neuropsychiatric disorders: a review of in vitro, animal and human studies.
    Lopresti AL
    J Psychopharmacol; 2017 Mar; 31(3):287-302. PubMed ID: 28135888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Psychiatric Inclusion and Exclusion Criteria in Placebo-Controlled Monotherapy Trials of Bipolar Depression: An Analysis of Studies of the Past 20 Years.
    Zimmerman M; Holst CG; Clark HL; Multach M; Walsh E; Rosenstein LK; Gazarian D
    CNS Drugs; 2016 Dec; 30(12):1209-1218. PubMed ID: 27541608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects.
    Lopresti AL; Hood SD; Drummond PD
    J Psychopharmacol; 2012 Dec; 26(12):1512-24. PubMed ID: 23035031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bipolar disorders.
    McIntyre RS; Berk M; Brietzke E; Goldstein BI; López-Jaramillo C; Kessing LV; Malhi GS; Nierenberg AA; Rosenblat JD; Majeed A; Vieta E; Vinberg M; Young AH; Mansur RB
    Lancet; 2020 Dec; 396(10265):1841-1856. PubMed ID: 33278937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of antidepressant use between subjects with bipolar disorder and major depressive disorder with or without comorbid anxiety.
    Schaffer A; Cairney J; Veldhuizen S; Cheung A; Levitt A
    J Clin Psychiatry; 2007 Nov; 68(11):1785-92. PubMed ID: 18052573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study.
    Lopresti AL; Maes M; Maker GL; Hood SD; Drummond PD
    J Affect Disord; 2014; 167():368-75. PubMed ID: 25046624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidepressant utilisation patterns and determinants of short-term and non-psychiatric use in the Finnish general adult population.
    Sihvo S; Isometsä E; Kiviruusu O; Hämäläinen J; Suvisaari J; Perälä J; Pirkola S; Saarni S; Lönnqvist J
    J Affect Disord; 2008 Sep; 110(1-2):94-105. PubMed ID: 18276016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychiatric and physical outcomes of long-term use of lithium in older adults with bipolar disorder and major depressive disorder: A cross-sectional multicenter study.
    Morlet E; Costemale-Lacoste JF; Poulet E; McMahon K; Hoertel N; Limosin F;
    J Affect Disord; 2019 Dec; 259():210-217. PubMed ID: 31446382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevalence of psychiatric disorders in French general practice using the patient health questionnaire: comparison with GP case-recognition and psychotropic medication prescription].
    Norton J; de Roquefeuil G; David M; Boulenger JP; Ritchie K; Mann A
    Encephale; 2009 Dec; 35(6):560-9. PubMed ID: 20004287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials.
    Zheng W; Zhu XM; Zhang QE; Cai DB; Yang XH; Zhou YL; Ungvari GS; Ng CH; He SH; Peng XJ; Ning YP; Xiang YT
    Schizophr Res; 2019 Jul; 209():12-21. PubMed ID: 31164254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics.
    Gao K; Kemp DE; Fein E; Wang Z; Fang Y; Ganocy SJ; Calabrese JR
    J Clin Psychiatry; 2011 Aug; 72(8):1063-71. PubMed ID: 21034695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin in depressive disorders: An overview of potential mechanisms, preclinical and clinical findings.
    Kaufmann FN; Gazal M; Bastos CR; Kaster MP; Ghisleni G
    Eur J Pharmacol; 2016 Aug; 784():192-8. PubMed ID: 27235294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce.
    Sarris J; Ravindran A; Yatham LN; Marx W; Rucklidge JJ; McIntyre RS; Akhondzadeh S; Benedetti F; Caneo C; Cramer H; Cribb L; de Manincor M; Dean O; Deslandes AC; Freeman MP; Gangadhar B; Harvey BH; Kasper S; Lake J; Lopresti A; Lu L; Metri NJ; Mischoulon D; Ng CH; Nishi D; Rahimi R; Seedat S; Sinclair J; Su KP; Zhang ZJ; Berk M
    World J Biol Psychiatry; 2022 Jul; 23(6):424-455. PubMed ID: 35311615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review.
    Fond G; Hamdani N; Kapczinski F; Boukouaci W; Drancourt N; Dargel A; Oliveira J; Le Guen E; Marlinge E; Tamouza R; Leboyer M
    Acta Psychiatr Scand; 2014 Mar; 129(3):163-79. PubMed ID: 24215721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.